Home › Leucemia mieloide acuta › New Jersey › Clifton
Studi clinici su Leucemia mieloide acuta a Clifton, NJ
12 studi su Leucemia mieloide acuta cercano partecipanti presso sedi a Clifton e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
In reclutamentoFase 1
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
In reclutamentoFase 3
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
In reclutamentoFase 3
- Hackensack University Medical Center, Hackensack · a 7 mi di distanza
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
In reclutamentoFase 2
- John Theurer Cancer Center at Hackensack UMC, Hackensack · a 7 mi di distanza
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
In reclutamentoFase 1/2
- Hackensack University Medical Center, Hackensack · a 7 mi di distanza
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
In reclutamentoFase 3
- Hackensack University Medical Center, HMH, Hackensack · a 7 mi di distanza
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
In reclutamentoFase 1
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · a 7 mi di distanza
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
In reclutamentoFase 2
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
In reclutamentoStudio osservazionale
- Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
In reclutamentoFase 2/3
- John Theurer Cancer Center / Hackensack University, Hackensack · a 7 mi di distanza
Phase IB/II of CPX-351 for Relapse Prevention in AML
In reclutamentoFase 1/2
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · a 7 mi di distanza
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
In reclutamentoFase 1
- Hackensack University Medical Center, Hackensack · a 7 mi di distanza
Studi su Leucemia mieloide acuta in altre città
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Seattle, WA41 studi
- Baldwin Park, CA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA31 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Altri studi a Clifton
- Cancro del polmone non a piccole cellule24 studi
- Cancro (tutti i tipi)15 studi
- Mieloma multiplo14 studi
- Cancro metastatico12 studi
- Cancro al seno12 studi
- Cancro alla prostata12 studi
- Cancro ovarico11 studi
- Cancro ai polmoni10 studi
- Cancro colorettale8 studi
- Carcinoma a cellule squamose della testa e del collo8 studi
- Cancro dell'endometrio8 studi
- Insufficienza cardiaca8 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.